|
|
|
| The Development of Antigen Testing for SARS-CoV-2 |
CHEN Chen1,2,HU Jin-chao1,2,CAO Shan-shan1,2,MEN Dong1,2,**( ) |
1 State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan 430071, China
2 University of Chinese Academy of Sciences, Beijing 100049, China |
|
|
|
Abstract The global pandemic of COVID-19 has taken a major impact on global public health, and social and economic operations. In the case of delays in drug development and insufficient verification of vaccine effectiveness, the priority is to take a large-scale rapid screening to filter out potential infections (especially mild and asymptomatic patients), isolate those infected patients centralized to cut off transmission routes and to protect the susceptible people. Therefore, early diagnosis of SARS-CoV-2 infection is particularly important. This paper summarizes the rapid detection products toward SARS-CoV-2 antigens in the current market, analyzes the global market of rapid SARS-CoV-2 antigen detection, outlines its research and development trends, and in the end discusses the prospects for developing the capability of independent innovation in new technologies and methods for SARS-CoV-2 antigen detection in our country.
|
|
Received: 10 May 2021
Published: 06 July 2021
|
|
|
|
Corresponding Authors:
Dong MEN
E-mail: d.men@wh.iov.cn
|
|
|
| [1] |
Lancet T. Emerging understandings of 2019-nCoV. Lancet, 2020, 395(10221):311.
doi: S0140-6736(20)30186-0
pmid: 31986259
|
|
|
| [2] |
Zhu N, Zhang D Y, Wang W L, et al. A novel coronavirus from patients with pneumonia in China, 2019. The New England Journal of Medicine, 2020, 382(8):727-733.
doi: 10.1056/NEJMoa2001017
pmid: 31978945
|
|
|
| [3] |
Wang C, Horby P W, Hayden F G, et al. A novel coronavirus outbreak of global health concern. Lancet, 2020, 395(10223):470-473.
doi: 10.1016/S0140-6736(20)30185-9
|
|
|
| [4] |
Tian H Y, Liu Y H, Li Y D, et al. An investigation of transmission control measures during the first 50 days of the COVID-19 epidemic in China. Science, 2020, 368(6491):638-642.
doi: 10.1126/science.abb6105
|
|
|
| [5] |
朱民. 新冠肺炎疫情对全球经济和金融市场造成的冲击. 国际金融, 2020,(4):3-5.
|
|
|
| [5] |
Zhu M. Impact of Novel coronavirus pneumonia on global economic and financial markets. International Finance, 2020,(4):3-5.
|
|
|
| [6] |
沈淑容, 马紫程, 许以灵, 等. 新型冠状病毒境外输入对我国疫情的影响. 浙江师范大学学报(自然科学版), 2021, 44(2):197-205.
|
|
|
| [6] |
Shen S R, Ma Z C, Xu Y L, et al. Epidemic impact of overseas-imported COVID-19 infected cases on China. Journal of Zhejiang Normal University (Natural Sciences), 2021, 44(2):197-205.
|
|
|
| [7] |
Yesudhas D, Srivastava A, Gromiha M M. COVID-19 outbreak: history, mechanism, transmission, structural studies and therapeutics. Infection, 2021, 49(2):199-213.
doi: 10.1007/s15010-020-01516-2
|
|
|
| [8] |
Prather K A, Wang C C, Schooley R T. Reducing transmission of SARS-CoV-2. Science, 2020, 368(6498):1422-1424.
doi: 10.1126/science.abc6197
|
|
|
| [9] |
Huang S Z, Jin Z, Peng Z H. Studies of the strategies for controlling the COVID-19 epidemic in China: Estimation of control efficacy and suggestions for policy makers. Scientia Sinica Mathematica, 2020, 50(6):885.
doi: 10.1360/SSM-2020-0043
|
|
|
| [10] |
Niu Y, Xu F J. Deciphering the power of isolation in controlling COVID-19 outbreaks. The Lancet Global Health, 2020, 8(4):e452-e453.
doi: 10.1016/S2214-109X(20)30085-1
|
|
|
| [11] |
Shen M W, Xiao Y N, Zhuang G H, et al. Mass testing-An underexplored strategy for COVID-19 control. The Innovation, 2021, 2(2):100114.
doi: 10.1016/j.xinn.2021.100114
|
|
|
| [12] |
Kerr C C, Mistry D, Stuart R M, et al. Controlling COVID-19 via test-trace-quarantine. Nature Communications, 2021, 12:2993.
doi: 10.1038/s41467-021-23276-9
|
|
|
| [13] |
Kim D, Lee J Y, Yang J S, et al. The architecture of SARS-CoV-2 transcriptome. Cell, 2020, 181(4): 914-921.e10.
doi: 10.1016/j.cell.2020.04.011
|
|
|
| [14] |
Amanat F, Krammer F. SARS-CoV-2 vaccines: status report. Immunity, 2020, 52(4):583-589.
doi: 10.1016/j.immuni.2020.03.007
|
|
|
| [15] |
Verdecchia P, Cavallini C, Spanevello A, et al. The pivotal link between ACE2 deficiency and SARS-CoV-2 infection. European Journal of Internal Medicine, 2020, 76:14-20.
doi: S0953-6205(20)30151-5
pmid: 32336612
|
|
|
| [16] |
Azkur A K, Akdis M, Azkur D, et al. Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19. Allergy, 2020, 75(7):1564-1581.
doi: 10.1111/all.v75.7
|
|
|
| [17] |
Long Q X, Tang X J, Shi Q L, et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nature Medicine, 2020, 26(8):1200-1204.
doi: 10.1038/s41591-020-0965-6
|
|
|
| [18] |
Li Y J, Ji D P, Cai W Y, et al. Clinical characteristics, cause analysis and infectivity of COVID‐19 nucleic acid repositive patients: A literature review. Journal of Medical Virology, 2021, 93(3):1288-1295.
doi: 10.1002/jmv.v93.3
|
|
|
| [19] |
Ortiz-Prado E, Simbaña-Rivera K, Gómez-Barreno L, et al. Clinical, molecular, and epidemiological characterization of the SARS-CoV-2 virus and the coronavirus disease 2019 (COVID-19), a comprehensive literature review. Diagnostic microbiology and infectious disease, 2020, 98(1):115094.
doi: S0732-8893(20)30471-5
pmid: 32623267
|
|
|
| [20] |
Arthur Ricardo Vilar Scavuzzi de Carvalho, Cezarotti Filho M L, Azevedo P C P D, et al. Epidemiology, diagnosis, treatment, and future perspectives concerning SARS-CoV-2: a review article. Revista Da Associacao Medica Brasileira (1992), 2020, 66(3):370-374.
doi: S0104-42302020000300370
pmid: 32520160
|
|
|
| [21] |
Yan Y, Chang L, Wang L N. Laboratory testing of SARS-CoV, MERS-CoV, and SARS-CoV-2 (2019-nCoV): Current status, challenges, and countermeasures. Reviews in Medical Virology, 2020, 30(3):e2106.
|
|
|
| [22] |
Ravi N, Cortade D L, Ng E, et al. Diagnostics for SARS-CoV-2 detection: a comprehensive review of the FDA-EUA COVID-19 testing landscape. Biosensors & Bioelectronics, 2020, 165:112454.
doi: 10.1016/j.bios.2020.112454
|
|
|
| [23] |
Zhang J, Ding N, Song Y Z, et al. Phylogenomic tracing of asymptomatic transmission in a COVID-19 outbreak. The Innovation, 2021, 2(2):100099.
doi: 10.1016/j.xinn.2021.100099
|
|
|
| [24] |
Jung J, Garnett E, Jariwala P, et al. Clinical performance of a semi-quantitative assay for SARS-CoV-2 IgG and SARS-CoV2 IgM antibodies. Clinica Chimica Acta, 2020, 510:790-795.
doi: 10.1016/j.cca.2020.09.023
|
|
|
| [25] |
Ayouba A, Thaurignac G, Morquin D, et al. Multiplex detection and dynamics of IgG antibodies to SARS-CoV-2 and the highly pathogenic human coronaviruses SARS-CoV and MERS-CoV. Journal of Clinical Virology, 2020, 129:104521.
doi: 10.1016/j.jcv.2020.104521
|
|
|
| [26] |
La Marca A, Capuzzo M, Paglia T, et al. Testing for SARS-CoV-2 (COVID-19): a systematic review and clinical guide to molecular and serological in-vitro diagnostic assays. Reproductive Biomedicine Online, 2020, 41(3):483-499.
doi: 10.1016/j.rbmo.2020.06.001
|
|
|
| [27] |
World Health Organization. Antigen-detection in the diagnosis of SARS-CoV-2 infection using rapid immunoassays: interim guidance-11 September 2020. Geneva: World Health Organization, 2020.
|
|
|
| [28] |
Mina M J, Peto T E, García-Fiñana M, et al. Clarifying the evidence on SARS-CoV-2 antigen rapid tests in public health responses to COVID-19. The Lancet, 2021, 397(10283):1425-1427.
doi: 10.1016/S0140-6736(21)00425-6
|
|
|
| [29] |
Bahadir E B, Sezgintürk M K. Lateral flow assays: Principles, designs and labels. TrAC Trends in Analytical Chemistry, 2016, 82:286-306.
doi: 10.1016/j.trac.2016.06.006
|
|
|
| [30] |
Oran D P, Topol E J. The proportion of SARS-CoV-2 infections that are asymptomatic. Annals of Internal Medicine, 2021, 174(5):655-662
doi: 10.7326/M20-6976
|
|
|
| [31] |
Simon V, van Bakel H, Sordillo E M. Positive, again! What to make of “re-positive” SARS-CoV-2 molecular test results. EBioMedicine, 2020, 60:103011.
doi: 10.1016/j.ebiom.2020.103011
|
|
|
| [32] |
罗银波, 吴杨, 刘漫, 等. 常态化新冠肺炎防控策略与机制的思考. 公共卫生与预防医学, 2020, 31(6):1-5.
|
|
|
| [32] |
Luo Y B, Wu Y, Liu M, et al. Thoughts on the strategy and mechanism for the regular prevention and control of COVID-19. Journal of Public Health and Preventive Medicine, 2020, 31(6):1-5.
|
|
|
| [33] |
Ghoshal S, Mitra D, Roy S, et al. Biosensors and biochips for nanomedical applications: a review. Sensors & Transducers, 2010, 113(2):1.
|
|
|
| [34] |
Vo-Dinh T, Cullum B. Biosensors and biochips: advances in biological and medical diagnostics. Fresenius’ Journal of Analytical Chemistry, 2000, 366(6-7):540-551.
doi: 10.1007/s002160051549
|
|
|
| [35] |
Slomovic S, Pardee K, Collins J J. Synthetic biology devices for in vitro and in vivo diagnostics. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112(47):14429-14435.
|
|
|
| [36] |
Sposito A J, Kurdekar A, Zhao J Q, et al. Application of nanotechnology in biosensors for enhancing pathogen detection. Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology, 2018, 10(5):e1512. DOI: 10.1002/wnan.1512.
|
|
|
| [37] |
Myers F B, Lee L P. Innovations in optical microfluidic technologies for point-of-care diagnostics. Lab on a Chip, 2008, 8(12):2015-2031.
doi: 10.1039/b812343h
|
|
|
| [38] |
Livingston A D, Campbell C J, Wagner E K, et al. Biochip sensors for the rapid and sensitive detection of viral disease. Genome Biology, 2005, 6(6):112.
pmid: 15960809
|
|
|
| [39] |
von Bomhard A, Elsässer A, Ritschl L M, et al. Cryopreservation of endothelial cells in various cryoprotective agents and media - vitrification versus slow freezing methods. PLoS One, 2016, 11(2):e0149660.
doi: 10.1371/journal.pone.0149660
|
|
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
| |
Shared |
|
|
|
|
| |
Discussed |
|
|
|
|
